Clinical and biochemical parameters during neuroleptic treatment. I. Investigations with haloperidol
- PMID: 981320
- DOI: 10.1055/s-0028-1094475
Clinical and biochemical parameters during neuroleptic treatment. I. Investigations with haloperidol
Abstract
26 patients with a paranoid-hallucinatory syndrome were treated with a fixed daily dose of haloperidol. Psychopathological symptoms and parkinsonism were studied before and during the treatment. HVA and 5-HIAA concentrations in CSF were determined immediately before and after 5 or 15 days of treatment. After 5 days of treatment a slight effect was observed on psychotic symptoms and on the extrapyramidal motor system, as well as an elevation of HVA and 5-HIAA concentrations in CSF. After 15 days of treatment the extrapyramidal and antipsychotic effects were significant, but the rise of HVA was smaller than after 5 days of treatment; 5-HIAA remained unchanged. These different time courses of the neuroleptic effects on psychopathological symptoms, on extrapyramidal system and on monoamine metabolites concentration in CSF could be interpreted as a development of drug tolerance in relation to the biochemical parameters.
Similar articles
-
Clinical and biochemical parameters during neuroleptic treatment. II. Antipsychotic effect of haloperidol in patients with chronic organic brain damage.Pharmakopsychiatr Neuropsychopharmakol. 1976 Jan;9(1):37-42. doi: 10.1055/s-0028-1094476. Pharmakopsychiatr Neuropsychopharmakol. 1976. PMID: 981321
-
Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients.Psychopharmacologia. 1975;40(4):341-50. doi: 10.1007/BF00421473. Psychopharmacologia. 1975. PMID: 1096218 Clinical Trial.
-
Concentrations of monoamine metabolites and chlorpromazine in cerebrospinal fluid for prediction of therapeutic response in psychotic patients treated with neuroleptic drugs.Prog Biochem Pharmacol. 1980;16:133-40. Prog Biochem Pharmacol. 1980. PMID: 6160594
-
CSF-changes of HVA and 5-HIAA during intermittent and continuous Parkinson therapy with particular regard to prodipin application.Pharmakopsychiatr Neuropsychopharmakol. 1978 Mar;11(2):76-80. doi: 10.1055/s-0028-1094565. Pharmakopsychiatr Neuropsychopharmakol. 1978. PMID: 347467 Clinical Trial.
-
Monoamine metabolites in human cerebrospinal fluid: indicators of neuronal activity?Med Biol. 1985;63(1):1-17. Med Biol. 1985. PMID: 2582215 Review.
Cited by
-
[Psychotropic drugs--real progress or danger? (author's transl)].Klin Wochenschr. 1977 Dec 15;55(24):1217-26. doi: 10.1007/BF01682287. Klin Wochenschr. 1977. PMID: 22774 German.
-
Endogenous ligands of a putative LSD-serotonin receptor in the cerebrospinal fluid: higher level of LSD-displacing factors (LDF) in unmedicated psychotic patients.Psychopharmacology (Berl). 1977 Aug 31;54(1):9-16. doi: 10.1007/BF00426533. Psychopharmacology (Berl). 1977. PMID: 410064 No abstract available.
-
The effect of propranolol on CSF amine metabolites in psychiatric patients.Br J Clin Pharmacol. 1983 Mar;15(3):331-7. doi: 10.1111/j.1365-2125.1983.tb01507.x. Br J Clin Pharmacol. 1983. PMID: 6189502 Free PMC article. Clinical Trial.
-
A New Look on an Old Issue: Comprehensive Review of Neurotransmitter Studies in Cerebrospinal Fluid of Patients with Schizophrenia and Antipsychotic Effect on Monoamine's Metabolism.Clin Psychopharmacol Neurosci. 2021 Aug 31;19(3):395-410. doi: 10.9758/cpn.2021.19.3.395. Clin Psychopharmacol Neurosci. 2021. PMID: 34294610 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources